Bipulendu Jena

TL;DR: Results show for the first time that donor-derived allogeneic anti-CD19-CAR T cells can cause regression of B-cell malignancies resistant to standard DLIs without causing GVHD.

TL;DR: The generation of clinical grade CAR(+) T cells is an example of bench-to-bedside translational science that has been accomplished using investigator-initiated trials operating largely without industry support, and the next-generation trials will deliver designer T cells with improved homing, CAR-mediated signaling, and replicative potential, as investigators move from the bedside to the bench and back again.

TL;DR: CD19-specific CAR T cells generated with Sleeping Beauty transposon/transposase platforms were safe, and may provide additional cancer control as planned infusions after HSCT, and support further clinical development of this nonviral gene therapy approach.

TL;DR: A novel anti-idiotype monoclonal antibody (mAb) to detect CD19-specific CAR+ T cells before and after their adoptive transfer and could be extended to other gene therapy trials targeting different tumor associated antigens in the context of CAR-based adoptive T-cell therapy.

TL;DR: The platform technologies of SB-mediated transposition and CAR-dependent propagation on aAPC were adapted for human application and initiated clinical trials in patients with high-risk B-lineage malignancies undergoing autologous and allogeneic hematopoietic stem-cell transplantation (HSCT).